ASTRAZEN - Technical Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Technical Rating: 3.6

Here’s a comprehensive technical analysis of ASTRAZEN (AstraZeneca Pharma India Ltd.)

📊 Trend Overview

Current Price: ₹8,894 is below the 50-DMA (₹8,995) but above the 200-DMA (₹8,043), suggesting short-term weakness but long-term bullish structure.

RSI (44.9): In the lower neutral zone, indicating lack of momentum and potential for further consolidation.

MACD (-20.8): Negative and diverging, signaling bearish momentum.

Volume: Below average (17,347 vs 23,611), showing weak participation and confirming consolidation.

📌 Conclusion: The stock is currently consolidating with a mild bearish bias in the short term.

📈 Chart Patterns & Indicators

Bollinger Bands: Price is near the lower band, suggesting oversold conditions and possible bounce-back.

Candlestick Patterns: Recent Doji and Bearish Engulfing patterns indicate indecision and selling pressure.

Support Levels

₹8,043 (200-DMA)

₹8,606 (Pivot S3)

Resistance Levels

₹9,119 (50-DMA zone)

₹9,681 – ₹9,962 (R2–R3 zone)

🎯 Entry & Exit Zones

Action Price Zone (₹) Rationale

Buy Entry 8,050 – 8,300 Near strong support, oversold RSI

Target 1 9,100 – 9,200 50-DMA resistance zone

Target 2 9,680 – 9,960 Upper resistance band

Stop Loss 7,850 Below 200-DMA and key support

🔍 Momentum Signals

Short-Term: Weak momentum, bearish MACD, low volume.

Medium-Term: Neutral to bullish bias supported by long-term moving averages.

Long-Term: Strong fundamentals (ROCE 33.4%, ROE 23.6%) and low debt (0.05) support resilience.

🧭 Final Take

ASTRAZEN is consolidating with short-term weakness but a structurally strong long-term setup. A bounce from ₹8,050–₹8,300 could offer a favorable entry, especially if volume picks up. Watch for a MACD crossover and RSI recovery above 50 for confirmation of trend reversal.

Want to compare this setup with other pharma stocks or explore sector-wide momentum next?

Edit in a page